Archived explainer. For the current picture see today's HROW page.
HARROW INC (HROW) is drawing unusual attention today. Our newswire has captured 1 story on HROW across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
HROW stock is moving modestly higher today amid anticipation of its second quarter 2026 earnings report scheduled for August 10, 2026. The announcement by Harrow Inc. that it will release its financial results after market close on that date has generated investor interest. Recent insider buying activity and ongoing product developments also contribute to the stock's movement.
Harrow Inc. announced on July 27, 2026, that it will report its second quarter 2026 financial results after the market closes on August 10, 2026. The company, which specializes in ophthalmic disease management solutions, has seen recent insider purchases by several board members and its CEO. Adrienne L. Graves, Lauren P. Silvernail, and Mark L. Baum have all made purchases within the past month, with the most recent transactions occurring on May 18 and May 14. These insider buys total $469,000 across four transactions and indicate confidence in the company's strategic direction.
In addition, Harrow has been active in product development and commercialization. The company recently launched BYOOVIZ, an FDA-approved biosimilar referencing LUCENTIS, and has presented multiple studies at the ASRS 2026 Annual Meeting. These developments highlight Harrow's ongoing efforts to expand its product portfolio and reinforce its position in the ophthalmic market.
Investors should focus on Harrow’s scheduled earnings report on August 10, 2026, for insights into the company's financial performance and future outlook. The report will provide a clearer picture of how Harrow is managing its operations amid a challenging earnings environment. Continued insider buying and product developments will also be key indicators of the company's momentum in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second...
More on HROW: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HROW move explainers: 2026-07-27 · 2026-07-21 · 2026-07-20